EA202092000A1 - Ингибиторы димеризации egfr и их использование - Google Patents
Ингибиторы димеризации egfr и их использованиеInfo
- Publication number
- EA202092000A1 EA202092000A1 EA202092000A EA202092000A EA202092000A1 EA 202092000 A1 EA202092000 A1 EA 202092000A1 EA 202092000 A EA202092000 A EA 202092000A EA 202092000 A EA202092000 A EA 202092000A EA 202092000 A1 EA202092000 A1 EA 202092000A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- dimerization inhibitors
- egfr dimerization
- egfr
- inhibitors
- cancer
- Prior art date
Links
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title abstract 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title abstract 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 title abstract 2
- 238000006471 dimerization reaction Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634452P | 2018-02-23 | 2018-02-23 | |
| PCT/US2019/019391 WO2019165358A1 (en) | 2018-02-23 | 2019-02-25 | Egfr dimer disruptors and use of the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202092000A1 true EA202092000A1 (ru) | 2020-12-09 |
Family
ID=67688515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202092000A EA202092000A1 (ru) | 2018-02-23 | 2019-02-25 | Ингибиторы димеризации egfr и их использование |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11358965B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3755323A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7497046B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102748047B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111886009A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019223168B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020017184A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3091834A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202092000A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020008767A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019165358A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019223168B2 (en) | 2018-02-23 | 2024-09-12 | The Regents Of The University Of Michigan | EGFR dimer disruptors and use of the same |
| CN119454706A (zh) * | 2019-08-22 | 2025-02-18 | 密歇根大学董事会 | 治疗kras相关癌症的方法 |
| IL296091A (en) * | 2020-03-05 | 2022-11-01 | Univ Michigan Regents | Inhibitors of braf, kras, egfr and other targets and their uses |
| CN115397413A (zh) * | 2020-03-05 | 2022-11-25 | 密歇根大学董事会 | Egfr、kras、braf和其他靶标的抑制剂及其用途 |
| MX2023003362A (es) | 2020-09-23 | 2023-05-30 | Scorpion Therapeutics Inc | Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer. |
| WO2022072645A2 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| TW202229282A (zh) | 2020-09-30 | 2022-08-01 | 美商史考皮恩治療有限公司 | 治療癌症之方法 |
| WO2022072632A1 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Bicyclic compounds for use in the treatment cancer |
| BR112023006531A2 (pt) | 2020-10-09 | 2023-10-03 | Scorpion Therapeutics Inc | Inibidores heterocílicos de egfr e/ou her2, para uso no tratamento de câncer |
| WO2022077154A1 (en) * | 2020-10-12 | 2022-04-21 | The Regents Of The University Of Michigan | Synthesis of egfr modulators |
| CN116997551A (zh) * | 2020-10-12 | 2023-11-03 | 密歇根大学董事会 | Egfr调节剂的合成 |
| WO2022094271A1 (en) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| WO2022197913A1 (en) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Bicyclic derivatives which can be used to treat cancer |
| KR20240016250A (ko) * | 2021-04-02 | 2024-02-06 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료를 위한 병용요법 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| WO2023173083A1 (en) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| WO2024254298A1 (en) | 2023-06-08 | 2024-12-12 | Scorpion Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
| EP4724150A1 (en) | 2023-06-08 | 2026-04-15 | Antares Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3547977A (en) | 1967-10-27 | 1970-12-15 | Velsicol Chemical Corp | Novel carbanilates |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US9029502B2 (en) | 2010-12-20 | 2015-05-12 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
| WO2014176475A2 (en) * | 2013-04-26 | 2014-10-30 | The Regents Of The University Of Michigan | Egfr inhibitors and uses thereof |
| EP3096761A1 (en) * | 2014-01-24 | 2016-11-30 | Confluence Life Sciences, Inc. | Substituted pyroolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases |
| WO2016105525A2 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Novel pyrimidines as egfr inhibitors and methods of treating disorders |
| AU2019223168B2 (en) * | 2018-02-23 | 2024-09-12 | The Regents Of The University Of Michigan | EGFR dimer disruptors and use of the same |
-
2019
- 2019-02-25 AU AU2019223168A patent/AU2019223168B2/en active Active
- 2019-02-25 CA CA3091834A patent/CA3091834A1/en active Pending
- 2019-02-25 US US16/970,655 patent/US11358965B2/en active Active
- 2019-02-25 KR KR1020207027147A patent/KR102748047B1/ko active Active
- 2019-02-25 BR BR112020017184-0A patent/BR112020017184A2/pt active Search and Examination
- 2019-02-25 CN CN201980020234.3A patent/CN111886009A/zh active Pending
- 2019-02-25 JP JP2020544510A patent/JP7497046B2/ja active Active
- 2019-02-25 EA EA202092000A patent/EA202092000A1/ru unknown
- 2019-02-25 EP EP19757355.3A patent/EP3755323A4/en active Pending
- 2019-02-25 MX MX2020008767A patent/MX2020008767A/es unknown
- 2019-02-25 WO PCT/US2019/019391 patent/WO2019165358A1/en not_active Ceased
-
2022
- 2022-05-09 US US17/739,358 patent/US11999731B2/en active Active
-
2024
- 2024-01-25 JP JP2024009496A patent/JP2024056735A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020017184A2 (pt) | 2020-12-22 |
| EP3755323A4 (en) | 2021-11-24 |
| US11999731B2 (en) | 2024-06-04 |
| MX2020008767A (es) | 2021-01-08 |
| KR102748047B1 (ko) | 2024-12-27 |
| AU2019223168A1 (en) | 2020-09-10 |
| CN111886009A (zh) | 2020-11-03 |
| AU2019223168B2 (en) | 2024-09-12 |
| EP3755323A1 (en) | 2020-12-30 |
| WO2019165358A1 (en) | 2019-08-29 |
| CA3091834A1 (en) | 2019-08-29 |
| US20220340572A1 (en) | 2022-10-27 |
| KR20200124709A (ko) | 2020-11-03 |
| US20200377503A1 (en) | 2020-12-03 |
| JP2024056735A (ja) | 2024-04-23 |
| JP2021514001A (ja) | 2021-06-03 |
| JP7497046B2 (ja) | 2024-06-10 |
| US11358965B2 (en) | 2022-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992497A1 (ru) | МОДУЛЯТОРЫ K-Ras | |
| MX2020008767A (es) | Disruptores del dímero egfr y uso de estos. | |
| MX2023015185A (es) | Degradadores de proteinas y usos de los mismos. | |
| EA202092590A1 (ru) | Пиридазиноны в качестве ингибиторов parp7 | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
| CY1120095T1 (el) | Αναστολεις της erk και μεθοδοι χρησης | |
| EA201992781A1 (ru) | Ингибиторы g12c kras и способы их применения | |
| PH12020552229A1 (en) | Il-11ra antibodies | |
| MX392368B (es) | Composiciones y metodos para el tratamiento del cancer | |
| PH12022550646A1 (en) | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use | |
| EA201892587A1 (ru) | Использование глутамат-модулирующих средств вместе с иммунотерапией для лечения рака | |
| EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
| EA201791884A1 (ru) | Химерные антигенные рецепторы против dll3 и способы применения | |
| MX2020006297A (es) | Variantes de cd19. | |
| BR112018008326A2 (pt) | composições e métodos para o tratamento de câncer | |
| MX2018008995A (es) | Combinacion de un agonista de ox40 y un agonista de 4-1bb para tratar el cancer. | |
| EA202091964A1 (ru) | КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
| MX382996B (es) | Inhibidores de pcna | |
| MX2024012294A (es) | RECEPTORES DE TGF-ß Y MÉTODOS DE USO | |
| PH12020551336A1 (en) | Anti-klk5 antibodies and methods of use | |
| JOP20190190B1 (ar) | معالجة سرطان | |
| EA201892287A1 (ru) | Фармацевтические комбинации для лечения рака | |
| EA201892368A1 (ru) | ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине |